Apimeds Pharmaceuticals US Inc (APUS) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Apimeds Pharmaceuticals U...

    NYSE: APUS · Real-Time Price · USD
    1.78
    0.06 (3.49%)
    At close: Oct 03, 2025, 3:59 PM
    1.85
    3.93%
    After-hours: Oct 03, 2025, 06:28 PM EDT

    Apimeds Pharmaceuticals US Inc Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a n/a n/a n/a
    Gross Profit
    		 n/a n/a n/a n/a
    Operating Income
    		 -1.28M -747.44K -639.53K -1.02M
    Interest Income
    		 2.82K 7.81K n/a n/a
    Pretax Income
    		 -1.39M -777.69K -668.67K -1.03M
    Net Income
    		 -1.39M -777.69K -668.67K -1.03M
    Selling & General & Admin
    		 1.28M 648.89K 271.53K 529.55K
    Research & Development
    		 n/a 98.54K 368K 489.94K
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 1.28M 747.44K 639.53K 1.02M
    Interest Expense
    		 117.72K 38.07K 29.14K 6.74K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 1.28M 747.44K 639.53K 1.02M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 11.53M 11.53M 11.53M 11.53M
    Shares Outstanding (Diluted)
    		 12.69M 12.69M 12.69M 12.69M
    EPS (Basic)
    		 -0.12 -0.07 -0.06 -0.09
    EPS (Diluted)
    		 -0.11 -0.06 -0.05 -0.08
    EBITDA
    		 -1.27M -739.63K -639.53K -1.02M
    EBIT
    		 -1.27M -739.63K -639.53K -1.02M
    Depreciation & Amortization
    		 n/a n/a n/a n/a

    Add to Watchlist